All In Biotech

Free tool

FAERS Monitor: Tembexa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214460 or its brand name (Tembexa, Brincidofovir). Reports on generic versions are filed under their own applications.

Reports

139

Serious

114

82% of reports

Hospitalization

42

Death reported

57

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use40
  • acute kidney injury27
  • adenovirus infection15
  • drug ineffective14
  • drug resistance12
  • graft versus host disease in gastrointestinal tract11
  • hypotension11
  • immune reconstitution inflammatory syndrome11
  • multiple organ dysfunction syndrome11
  • condition aggravated9
  • cytomegalovirus infection9
  • pancytopenia9
  • respiratory failure9
  • acute graft versus host disease in skin8
  • diarrhoea8

Reports by year received

View as table
YearReports
20152
201617
201712
20189
201923
20209
20217
20224
202319
202422
202511
20264

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,020 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
adenovirus infectionSignal15786.7487.110,943
graft versus host disease in gastrointestinal tractSignal11786.3445.27,820
acute graft versus host disease in skinSignal8439.2223.93,065
immune reconstitution inflammatory syndromeSignal11334.8189.73,328
cytomegalovirus infectionSignal982.043.6641
drug resistanceSignal1270.741.2757
multiple organ dysfunction syndromeSignal1158.833.3569
acute kidney injurySignal2726.719.0647
pancytopeniaSignal924.413.0179
respiratory failureSignal918.79.9134
hypotensionSignal118.34.764
off label useSignal406.95.3205
condition aggravatedSignal94.52.421
diarrhoea81.91.03
drug ineffective141.61.03

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.